Duke logo

105SAR301 (Angiosarcoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and effective the study drugs are given alone and in combination with each other in patients diagnosed with angiosarcomas.

What is the Condition Being Studied?

Advanced Angiosarcoma

Who Can Participate in the Study?

Adults diagnosed with advance angiosarcoma that cannot be surgically removed.

Age Group
Adults

What is Involved?

This study has two parts, Screening and Treatment.

During Screening, you will have:
- Blood draws and possible tumor tissue biopsy
- A physical exam

If you qualify for the study you will be randomized (like the flip of a coin) to Treatment Group A or B
Group A- you will take the study drug (Pazopanib) by mouth every day
Group B- you will take the study drugs (pazopanib and TRC105); Pazopanib is taken by mouth and TRC105 is given intravenously.

You will stay in the study until your disease gets worse, or your study doctor requests you stop has you stop

Study Details

Full Title
A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib alone in Patients with Advanced Angiosarcoma (TAPPAS)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00080349
NCT:NCT02979899
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698